Skip to main content
Top

03-05-2024 | Epstein-Barr Virus | Original Article

Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH

Authors: Dan Tomomasa, Kay Tanita, Yuriko Hiruma, Akihiro Hoshino, Ko Kudo, Shohei Azumi, Mitsutaka Shiota, Masayoshi Yamaoka, Katsuhide Eguchi, Masataka Ishimura, Yuka Tanaka, Keiji Iwatsuki, Keisuke Okuno, Asahito Hama, Ken-Ichi Sakamoto, Takashi Taga, Kimitoshi Goto, Haruka Ota, Akihiro Ichiki, Kaori Kanda, Takako Miyamura, Saori Endo, Hidenori Ohnishi, Yoji Sasahara, Ayako Arai, Benjamin Fornier, Ken-Ichi Imadome, Tomohiro Morio, Sylvain Latour, Hirokazu Kanegane

Published in: International Journal of Hematology

Login to get access

Abstract

When Epstein-Barr virus (EBV) infection is suspected, identification of infected cells is important to understand the pathogenesis, determinine the treatment strategy, and predict the prognosis. We used the PrimeFlow™ RNA Assay Kit with a probe to detect EBV-encoded small RNAs (EBERs) and multiple surface markers, to identify EBV-infected cells by flow cytometry. We analyzed a total of 24 patients [11 with chronic active EBV disease (CAEBV), 3 with hydroa vacciniforme lymphoproliferative disorder, 2 with X-linked lymphoproliferative disease type 1 (XLP1), 2 with EBV-associated hemophagocytic lymphohistiocytosis, and 6 with posttransplant lymphoproliferative disorder (PTLD)]. We compared infected cells using conventional quantitative PCR methods and confirmed that infected cell types were identical in most patients. Patients with CAEBV had widespread infection in T and NK cells, but a small amount of B cells were also infected, and infection in patients with XLP1 and PTLD was not limited to B cells. EBV-associated diseases are believed to be complex pathologies caused by EBV infecting a variety of cells other than B cells. We also demonstrated that infected cells were positive for HLA-DR in patients with CAEBV. EBER flow FISH can identify EBV-infected cells with high sensitivity and is useful for elucidating the pathogenesis.
Appendix
Available only for authorised users
Literature
2.
go back to reference Fournier B, Latour S. Immunity to EBV as revealed by immunedeficiencies. Curr Opin Immunol. 2021;72:107–15.CrossRefPubMed Fournier B, Latour S. Immunity to EBV as revealed by immunedeficiencies. Curr Opin Immunol. 2021;72:107–15.CrossRefPubMed
3.
go back to reference Just T, Burgwald H, Broe MK. Flow cytometric detection of EBV (EBER snRNA) using peptide nucleic acid probes. J Virol Methods. 1998;73:163–74.CrossRefPubMed Just T, Burgwald H, Broe MK. Flow cytometric detection of EBV (EBER snRNA) using peptide nucleic acid probes. J Virol Methods. 1998;73:163–74.CrossRefPubMed
4.
go back to reference Kimura H, Miyake K, Yamauchi Y, Nishiyama K, Iwata S, Iwatsuki K, et al. Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lymphoproliferative diseases. J Infect Dis. 2009;200:1078–87.CrossRefPubMed Kimura H, Miyake K, Yamauchi Y, Nishiyama K, Iwata S, Iwatsuki K, et al. Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lymphoproliferative diseases. J Infect Dis. 2009;200:1078–87.CrossRefPubMed
5.
go back to reference Kawabe S, Ito Y, Gotoh K, Kojima S, Matsumoto K, Kinoshita T, et al. Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases. Cancer Sci. 2012;103:1481–1448.CrossRefPubMedPubMedCentral Kawabe S, Ito Y, Gotoh K, Kojima S, Matsumoto K, Kinoshita T, et al. Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases. Cancer Sci. 2012;103:1481–1448.CrossRefPubMedPubMedCentral
6.
go back to reference Fournier B, Boutboul D, Bruneau J, Miot C, Boulanger C, Malphettes M, et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J Exp Med. 2020;217: e20192262.CrossRefPubMedPubMedCentral Fournier B, Boutboul D, Bruneau J, Miot C, Boulanger C, Malphettes M, et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J Exp Med. 2020;217: e20192262.CrossRefPubMedPubMedCentral
7.
go back to reference Ohga S, Ishimura M, Yoshimoto G, Miyamoto T, Takada H, Tanaka T, et al. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK-cell lymphoproliferative disorders of childhood. J Clin Virol. 2011;51:31–7.CrossRefPubMed Ohga S, Ishimura M, Yoshimoto G, Miyamoto T, Takada H, Tanaka T, et al. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK-cell lymphoproliferative disorders of childhood. J Clin Virol. 2011;51:31–7.CrossRefPubMed
8.
go back to reference Kanegane H, Wado T, Nunogami K, Seki H, Taniguchi N, Tosato G. Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. Br J Haematol. 1996;95:116–22.CrossRefPubMed Kanegane H, Wado T, Nunogami K, Seki H, Taniguchi N, Tosato G. Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. Br J Haematol. 1996;95:116–22.CrossRefPubMed
9.
go back to reference Arai A. Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr. 2019;7:14.CrossRefPubMedPubMedCentral Arai A. Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr. 2019;7:14.CrossRefPubMedPubMedCentral
10.
go back to reference Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2023;482:227–44.CrossRefPubMed Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2023;482:227–44.CrossRefPubMed
11.
go back to reference Meazza R, Tuberosa C, Cetica V, Falco M, Parolini S, Grieve S, et al. Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2014;134:1381–7.CrossRefPubMedPubMedCentral Meazza R, Tuberosa C, Cetica V, Falco M, Parolini S, Grieve S, et al. Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2014;134:1381–7.CrossRefPubMedPubMedCentral
12.
go back to reference Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefPubMed Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefPubMed
13.
go back to reference Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003;31:145–55.CrossRefPubMed Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003;31:145–55.CrossRefPubMed
14.
go back to reference Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37:132–6.CrossRefPubMedPubMedCentral Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37:132–6.CrossRefPubMedPubMedCentral
15.
go back to reference Watanabe Y, Sasahara Y, Satoh M, Looi CY, Katayama S, Suzuki T, et al. A case series of CAEBV of children and young adults treated with reduced-intensity conditioning and allogeneic bone marrow transplantation: a single-center study. Eur J Haematol. 2013;91:242–8.CrossRefPubMed Watanabe Y, Sasahara Y, Satoh M, Looi CY, Katayama S, Suzuki T, et al. A case series of CAEBV of children and young adults treated with reduced-intensity conditioning and allogeneic bone marrow transplantation: a single-center study. Eur J Haematol. 2013;91:242–8.CrossRefPubMed
16.
go back to reference Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280–6.CrossRefPubMed Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280–6.CrossRefPubMed
17.
go back to reference Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119:673–86.CrossRefPubMed Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119:673–86.CrossRefPubMed
18.
go back to reference Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4:404–13.CrossRefPubMed Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4:404–13.CrossRefPubMed
19.
go back to reference J Wang M Su N Wei H Yan J Zhang Y Gong et al 2023 Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells [published online ahead of print, 2023 Oct 12]. Blood blood.2023021074. J Wang M Su N Wei H Yan J Zhang Y Gong et al 2023 Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells [published online ahead of print, 2023 Oct 12]. Blood blood.2023021074.
20.
go back to reference Iwatsuki K, Miyake T, Hirai Y, Yamamoto T. Hydroa vacciniforme: a distinctive form of Epstein-Barr virus-associated T-cell lymphoproliferative disorders. Eur J Dermatol. 2019;29:21–8.CrossRefPubMed Iwatsuki K, Miyake T, Hirai Y, Yamamoto T. Hydroa vacciniforme: a distinctive form of Epstein-Barr virus-associated T-cell lymphoproliferative disorders. Eur J Dermatol. 2019;29:21–8.CrossRefPubMed
21.
go back to reference Toga A, Wada T, Sakakibara Y, Mase S, Araki R, Tone Y, et al. Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. J Infect Dis. 2010;201:1923–32.CrossRefPubMed Toga A, Wada T, Sakakibara Y, Mase S, Araki R, Tone Y, et al. Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. J Infect Dis. 2010;201:1923–32.CrossRefPubMed
22.
go back to reference Yang X, Wada T, Imadome K, Nishida N, Mukai T, Fujiwara M, et al. Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2. Herpesviridae. 2012;3:1.CrossRefPubMedPubMedCentral Yang X, Wada T, Imadome K, Nishida N, Mukai T, Fujiwara M, et al. Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2. Herpesviridae. 2012;3:1.CrossRefPubMedPubMedCentral
23.
go back to reference Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8:173–83.CrossRefPubMedPubMedCentral Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8:173–83.CrossRefPubMedPubMedCentral
24.
go back to reference Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B, et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol. 1997;71(6):4657–62.CrossRefPubMedPubMedCentral Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B, et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol. 1997;71(6):4657–62.CrossRefPubMedPubMedCentral
Metadata
Title
Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH
Authors
Dan Tomomasa
Kay Tanita
Yuriko Hiruma
Akihiro Hoshino
Ko Kudo
Shohei Azumi
Mitsutaka Shiota
Masayoshi Yamaoka
Katsuhide Eguchi
Masataka Ishimura
Yuka Tanaka
Keiji Iwatsuki
Keisuke Okuno
Asahito Hama
Ken-Ichi Sakamoto
Takashi Taga
Kimitoshi Goto
Haruka Ota
Akihiro Ichiki
Kaori Kanda
Takako Miyamura
Saori Endo
Hidenori Ohnishi
Yoji Sasahara
Ayako Arai
Benjamin Fornier
Ken-Ichi Imadome
Tomohiro Morio
Sylvain Latour
Hirokazu Kanegane
Publication date
03-05-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Hematology
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-024-03786-0
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine